Acadia Q2 Revenue Jumps 16%, Raises Full-Year Outlook on Strong DAYBUE and NUPLAZID Sales
ACAD sits 38% above its 52-week low of $19.69.
Summary
Acadia Pharmaceuticals reported Q2 2026 revenue of $308 million, up 16% year-over-year, and raised its full-year revenue guidance. DAYBUE sales surged 30% to $125 million, while NUPLAZID grew 10% to $183 million. The company also lowered R&D expense guidance and highlighted a strong cash position of $956 million.
Updates
· Reuters — Net income swung to $31.5 million from a prior-year loss.
Key Events · Earnings and Guidance · ACAD
-
Q2 Revenue Beats Expectations
Total revenues reached $308 million, a 16% increase year-over-year, driven by DAYBUE ($125 million, +30%) and NUPLAZID ($183 million, +10% on an adjusted basis).
-
Full-Year Guidance Raised
Management increased 2026 total revenue guidance to $1.24–$1.30 billion (from $1.22–$1.28 billion), with DAYBUE guidance raised to $480–$510 million and NUPLAZID reaffirmed at $760–$790 million.
-
R&D Expense Guidance Lowered
R&D expense guidance was reduced to $355–$380 million (from $385–$410 million), which may improve operating margins.
-
Strong Cash Position
Cash, cash equivalents, and investments totaled $956 million at quarter-end, up from $820 million at year-end 2025, providing ample runway for pipeline development.
Analysis · ACAD · Life Sciences
A strong second quarter saw total revenue climb 16% to $308 million, fueled by a 30% surge in DAYBUE and a 10% adjusted increase in NUPLAZID. Reflecting confidence in both franchises, management raised full-year revenue guidance to $1.24–$1.30 billion and lowered R&D expense guidance, a move that could bolster profitability. With $956 million in cash and no debt, the company is well-funded to advance its pipeline. A key catalyst looms: the Phase 2 remlifanserin readout in Alzheimer's disease psychosis, expected in September–October 2026, which could significantly expand the addressable market.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.7% of the 1075 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.60%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACAD was trading at $27.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6B. The 52-week trading range was $19.69 to $28.35. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.